Novel Compounds for the Treatment of Sepsis and Septic Shock

File # 98KUMC177

Description of Technology:  Sepsis is the leading cause of death in surgical intensive care units with mortality rates over 35%.  Despite considerable efforts to improve therapy over the last 50 years, no significant reduction in the mortality of patients has occurred since the introduction of antibiotics.  It is well recognized that lipopolysaccharides (LPS), which are the structural components of the outer membrane of gram negative bacteria, play a pivotal role in the sepsis syndrome.  The toxic center of the LPS molecule is a glycolipid moiety call lipid "A", whose structure is highly conserved among gram-negative bacteria and a logical target for developing therapeutics against sepsis.

Researchers at KU Medical Center have developed synthetic cationic amphiphilic molecules to bind and sequester bacterial LPS and inhibit its toxicity in vitro and in vivo.  Such molecules also appear to inhibit the deleterious effects of the administration of Gram-positive organisms, presumably by sequestration and subsequent neutralization of one or more species of molecules present in Gram-positive organisms that bear some physiochemical similarities of LPS.

Filed of Applications:  Sepsis and Septic Shock

Potential Advantages: 

• Low cost, effective, and broad-spectrum therapeutic agents for the treatment of sepsis and septic shock
• May enhance the effect of Gram-positive and/or Gram-negative sepsis or septic shock associated with speticemia
• The agents may enhance the effect of systemic antibiotic therapy by reducing or preventing pathological sequelae.

Stage of Development:  Near IND filing optimization

Patent Status: Patent # 5,998,482
 
Licensing Availability: Exclusive or Non-Exclusive Licenses. Please contact the Technology Transfer Office
at 913-588-5721 for more information.